18 september 2017: Lees ook dit artikel: https://kanker-actueel.nl/NL/immuuntherapie-met-provenge-spirutacel-t-geeft-betere-resultaten-op-overall-overleving-bij-gevorderde-prostaatkanker-als-deze-gevolgd-wordt-door-dendritische-celtherapie.html

4 augustus 2011: Bron: Ther Adv Med Oncol. 2011 March; 3(2): 101–108. doi: 10.1177/1758834010397692

Provenge - Sipuleucel-T, blijkt in combinatie met dendritische celtherapie te zorgen voor een significante levensverlenging bij mannen met hormoon resistente prostaatkanker. Dit was al eerder bekend gemaakt , maar nu zijn nieuwe analyses van fase II en III studies openbaar gemaakt en is er een update gemaakt van de resultaten. Klik hier voor het volledige studierapport in therapeutic advances in Medical oncology. Hieronder het abstract van de meest recente studie. Daaronder een referentielijst van studies gedaan met Provenge - Sipuleucel-T, die een mooi overzicht geven van de ontwikkeling en ook wel de beperkingen van Provenge - Sipuleucel-T.

Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists

Source: Ther Adv Med Oncol. 2011 March; 3(2): 101–108. doi: 10.1177/1758834010397692

Ther Adv Med Oncol. 2011 Mar;3(2):101-8.

Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists.

Garcia JA.

Source

Director, Advanced Prostate Cancer Program, Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue/R35, Cleveland, OH 44195, USA Garciaj4@ccf.org.

Abstract

Sipuleucel-T represents a novel immunotherapeutic compound designed to stimulate an immune response against castration-resistant prostate cancer (CRPC). Sipuleucel-T is an autologous active cellular immunotherapy product, which includes autologous dendritic cells pulsed ex vivo with PAP2024, a recombinant fusion protein made of prostatic acid phosphatase and granulocyte-macrophage colony-stimulating factor. Despite the lack of prostate-specific antigen and objective response, a recent phase III randomized trial demonstrated a significant improvement in overall survival in asymptomatic and minimally symptomatic CRPC patients. This review summarizes the clinical development of Sipuleucel-T in CRPC that led to the regulatory approval of this compound in the USA.

PMID:: 21789160; [PubMed - in process]
PMCID: PMC3126040

References:

Antonarakis E.S., Drake C.G. (2010) Current status of immunological therapies for prostate cancer. Curr Opin Urol 20: 241–246. [PubMed]
Armstrong A.J., Garrett-Mayer E., OuYang Y.C., Carducci M.A., Tannock I., deWit R., et al. (2007) Prostate specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 25: 3965–3970. [PubMed]
Beinart G., Rini B.I., Weinberg V., Small E.J. (2005) Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 4: 55–60. [PubMed]
Burch P.A., Croghan G.A., Gastineau D.A., Jones L.A., Kaur J.S., Kylstra J.W., et al. (2004) Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: A Phase 2 trial. Prostate 60: 197–204. [PubMed]
Chi K.N., Bjartell A., Dearnaley D., Saad F., Schröder F.H., Sternberg C., et al. (2009) Castration-resistant prostate cancer: From new pathophysiology to new treatment targets. Eur Urol 56: 594–605. [PubMed]
Coffey D.S., Isaacs J.T. (1981) Control of prostate growth. Urology 17: 17–24. [PubMed]
Goldstein N.S. (2002) Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 117: 471–477. [PubMed]
Haines A.M., Larkin S.E., Richardson A.P., Stirling R.W., Heyderman E. (1989) A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 60: 887–892. [PMC free article] [PubMed]
Halabi S., Small E.J., Kantoff P.W., Kattan M.W., Kaplan E.B., Dawson N.A., et al. (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21: 1232–1237. [PubMed]
Halabi S., Vogelzang N.J., Ou S.S., Owzar K., Archer L., Small E.J. (2009) Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 27: 2766–2771. [PMC free article] [PubMed]
Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with Sipuleucel-T in advanced prostate cancer. Cancer 115: 3670–3679. [PubMed]
Jemal A., Siegel R., Xu J., Ward E. (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5): 277–300. [PubMed]
Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411–422. [PubMed]
Lieschke G.J., Burgess A.W. (1992) Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med 372: 28–35. [PubMed]
Oh W.K., Kantoff P.W. (1998) Management of hormone refractory prostate cancer: Current standards and future prospects. J Urol 1160: 1220–1229. [PubMed]
Rhodes D.R., Barrette T.R., Rubin M.A., Ghosh D., Chinnaiyan A.M. (2002) Meta-analysis of microarrays: Interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427–4433. [PubMed]
Rini B.I., Weinberg V., Fong L., Conry S., Hershberg R.M., Small E.J. (2006) Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 107: 67–74. [PubMed]
Scher H.I., Halabi S., Tannock I., Morris M., Sternberg C.N., Carducci M.A., et al. (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26: 1148–1159. [PubMed]
Smaletz O., Scher H.I., Small E.J., Verbel D.A., McMillan A., Regan K., et al. (2002) Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20: 3972–3982. [PubMed]
Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., et al. (2000) Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. Clin Oncol 18: 3894–3903.
Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. (2006) Placebo-controlled phase III trial of immunologic therapy with Sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24: 3089–3094. [PubMed]
Steinman R.M. (1991) The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271–296. [PubMed]
Taylor B.S., Varambally S., Chinnaiyan A.M. (2006) Differential proteomic alterations between localized and metastatic prostate cancer. Br J Cancer 95: 425–430. [PMC free article] [PubMed]
Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., et al. (2005) Autoantibody signatures in prostate cancer. N Engl J Med 353: 1224–1235. [PubMed]